Arrowhead Pharmaceuticals (ARWR) closed at $58.16 on November 6, 2026, up 1.2% from the previous close, on volume of 1,268,777 shares (30-day average 1,674,154).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 9, 2026 | 16-Oct-26 75 P : 18-Dec-26 75 C : 18-Dec-26 75 P | 900 | |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Arrowhead reports lower pancreatitis rates, early cholesterol drug results
Seeking Alpha News (Sun, 8-Nov 12:19 PM ET)
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and more
Seeking Alpha News (Sun, 8-Nov 8:07 AM ET)
Business Wire (Sat, 7-Nov 4:15 PM ET)
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha News (Sat, 7-Nov 11:36 AM ET)
H.C. Wainwright Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
TipRanks (Thu, 5-Nov 6:36 AM ET)
Arrowhead Pharmaceuticals Refinances Debt With New $400 Million Loan
TipRanks (Wed, 4-Nov 8:01 AM ET)
Business Wire (Wed, 4-Nov 7:30 AM ET)
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Business Wire (Tue, 3-Nov 4:00 PM ET)
Business Wire (Mon, 2-Nov 7:30 AM ET)
Business Wire (Tue, 27-Oct 11:36 AM ET)
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Arrowhead Pharmaceuticals trades on the NASDAQ stock market under the symbol ARWR.
As of November 6, 2026, ARWR stock price climbed to $58.16 with 1,268,777 million shares trading.
ARWR has a beta of 1.68, meaning it tends to be more sensitive to market movements. ARWR has a correlation of 0.15 to the broad based SPY ETF.
ARWR has a market cap of $8.19 billion. This is considered a Mid Cap stock.
Last quarter Arrowhead Pharmaceuticals reported $75 million in Revenue and -$1.36 earnings per share. This beat revenue expectation by $24 million and missed earnings estimates by -$.17.
In the last 3 years, ARWR traded as high as $95.49 and as low as $9.57.
The top ETF exchange traded funds that ARWR belongs to (by Net Assets): IJH, VTI, VB, VBK, XBI.
ARWR has outperformed the market in the last year with a price return of +46.9% while the SPY ETF gained +10.8%. However, in the short term, ARWR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -32.2% vs -4.1% return in SPY. But in the last 2 weeks, ARWR shares have fared better than the market returning +0.2% compared to SPY -3.2%.
ARWR support price is $55.70 and resistance is $59.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARWR shares will trade within this expected range on the day.
